The rising prevalence of prostate cancer has been attributed to the increasing use of prostate-specific antigen (PSA) screening, a practice that has improved early detection but also raised concerns about overdiagnosis [4,5,6]. This evidence concerns the gene KLK3 and prostate carcinoma.